NCT00154713Unknown1 期
A Phase I/II Clinical Study of Immunotherapy for Advanced Colorectal Cancers Using CEA-Pulsed Dendritic Cells Mixed With Tetanus Toxoid and Subsequent IL-2 Treatment
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- evaluate the clinical responses of vaccinated patients 6 weeks after the first injection
研究概览
简要总结
The specific aims of this study are as follows:
- Primary endpoint: to evaluate the clinical responses of vaccinated patients.
- Secondary endpoint: to evaluate the safety of this treatment and the immune responses against CEA before and after the treatment
详细描述
In this trial, we will immunize metastatic colorectal cancer patients with recombinant CEA-pulsed DCs mixed with tetanus toxoid by subcutaneous injection. Low dose IL-2 will be given subcutaneously following DC vaccination to boost the growth of T cells. We will adapt "Simon's optimal two-stage design" for this study. In the first stage, we will treat 12 patients to evaluate the safety of this new protocol. If there are no severe toxicities/side effects and there is at least one patient that had stable disease or better clinical response, then we will proceed to the second stage and treat additional 25 patients. We will follow the clinical outcome of these 37 patients. The immune responses against CEA before and after vaccination will be examined.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have metastatic colorectal cancer.
- •Patients must have at least one measurable lesion.
- •Patients'serum level of CEA must be higher than 5 times of the normal value
- •Patients'disease must have failed chemotherapy with 5FU, CPT-11 or oxaliplatin.
- •Patients who are unsuitable or refuse chemotherapy will be considered eligible for this trial.
- •Patients'age must be 20 or greater.
- •Patients'estimated life expectancy is more than 3 months.
- •Patients must have adequate bone marrow function, defined as WBC >= 3500/mm3, neutrophil >= 1500/mm3, lymphocyte >= 1,000/mm3, and platelet >= 100,000/mm
- •Patients must have adequate liver and renal function, defined as serum alanine transaminase (ALT) and aspartate transaminase (AST) =< 5 times normal, bilirubin =< 1.5 times normal range, and creatinine =< 2 times upper normal limit.
- •All patients should have documentation of negative result of penicillin test.
- •Women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- •All patients must be informed of the investigational nature of this study and must sign and give written informed consent.
排除标准
- •Patients who have central nervous system metastasis except for those whose CNS disease has been treated with radiotherapy and/or surgery and has been stable for at least two weeks
- •Patients who have active acute or chronic infection (at the discretion of the investigator).
- •Pregnant or breast-nursing women
- •Patients who have active cardiac disease requiring therapy for failure, angina, arrythmia, or infarction within the preceding 6 months (exception: any patient whose cardiac failure is compensated on medications)
- •Patients who have asthma
- •Patients who have autoimmune disease such as inflammatory bowel disease, lupus erythematosus, ankylosing spondylitis, scleroderma, and multiple sclerosis
- •Patients who have serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)
- •Patients who have other prior or concurrent malignancy except for in-situ-carcinoma of cervix or adequately treated basal cell carcinoma of skin.
- •Patients who received chemotherapy, steroid or biologic treatment within 4 weeks prior to enrollment
结局指标
主要结局
evaluate the clinical responses of vaccinated patients 6 weeks after the first injection
次要结局
- evaluate the safety of this treatment and the immune responses against CEA before and after the treatment 6 weeks after the first injection
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Induction of Transplant Tolerance in LDLT Via iTSLiving-donor Liver TransplantationNCT04950842Juntendo University10
已完成
1 期
A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing MalignanciesBreast CancerColorectal CancerLung CancerColon CancerPancreatic CancerNCT00529984AlphaVax, Inc.28
终止
2 期
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.Advanced or Metastatic Gastric CancerAdvanced or Metastatic Gastroesophageal Junction CarcinomaNCT05188209Lepu Biopharma Co., Ltd.6
已完成
1 期
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate CancerCancer of the ProstateNCT01897207Cantonal Hospital of St. Gallen15
Unknown
1 期
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)Cancer.Melanoma.Ovarian Cancer.Lung Cancer.NCT01584115Instituto de Investigação em Imunologia15